Cara Therapeutics has been granted a patent for formulations enabling oral delivery of kappa opioid receptor agonists, including CR845. The formulations consist of the agonist, an oligosaccharide stabilizing agent, and an optional absorption enhancer. These capsules can be used for treating various conditions like pain, pruritus, and inflammation. GlobalData’s report on Cara Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cara Therapeutics, Tetrapeptide derivatives was a key innovation area identified from patents. Cara Therapeutics's grant share as of May 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Oral formulation for kappa opioid receptor agonist delivery
A recently granted patent (Publication Number: US11986509B2) discloses a formulation designed for the oral delivery of a kappa opioid receptor agonist, specifically CR845. The formulation includes particles containing the kappa opioid receptor agonist and an oligosaccharide, with the option to further include absorption enhancers like sodium caprate, lauroyl L-carnitine, and a quaternary ammonium salt. Additionally, the formulation may consist of various pharmaceutically acceptable components such as diluents, excipients, and carriers to enhance its efficacy.
Moreover, the patent claims cover the creation of pharmaceutically acceptable forms of the formulation, including tablets, caplets, capsules, powders, slurries, liquid suspensions, or gels, with the possibility of enteric coating for certain forms. The manufacturing method involves spray drying a mixture of CR845 and trehalose to produce the desired particles. The formulation's versatility allows for different absorption enhancers and other agents like binding agents and chelating agents to be included, offering a comprehensive approach to oral delivery of the kappa opioid receptor agonist CR845.
To know more about GlobalData’s detailed insights on Cara Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
